[
  {
    "ts": null,
    "headline": "U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer",
    "summary": "NEW YORK & TOKYO, November 21, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy",
    "url": "https://finnhub.io/api/news?id=5ad23ecbbc4e606f2dafba2fdfff3cdcf046e1fdb84033999fda5018305eaf7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763749440,
      "headline": "U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer",
      "id": 137572328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK & TOKYO, November 21, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy",
      "url": "https://finnhub.io/api/news?id=5ad23ecbbc4e606f2dafba2fdfff3cdcf046e1fdb84033999fda5018305eaf7a"
    }
  },
  {
    "ts": null,
    "headline": "The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing",
    "summary": "Watch the Video I began the conversation with Lee by noting how rarely investors stop to consider how dramatically the upper ranks of the stock market have changed. When we looked back twenty five years, the list of dominant companies in the S&P 500 was almost unrecognizable compared with today. What the Top of the ... The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing",
    "url": "https://finnhub.io/api/news?id=aac65bbbf2591460c01a92f35563646ac12210d5bcccf48485f8018e9ecfa773",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763735672,
      "headline": "The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing",
      "id": 137571860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Watch the Video I began the conversation with Lee by noting how rarely investors stop to consider how dramatically the upper ranks of the stock market have changed. When we looked back twenty five years, the list of dominant companies in the S&P 500 was almost unrecognizable compared with today. What the Top of the ... The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing",
      "url": "https://finnhub.io/api/news?id=aac65bbbf2591460c01a92f35563646ac12210d5bcccf48485f8018e9ecfa773"
    }
  },
  {
    "ts": null,
    "headline": "Is Trending Stock Pfizer Inc. (PFE) a Buy Now?",
    "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=98819c1a576df2f09f5c64a3fc77f2947503ad5f48e1813761ff09cc7d7b4040",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763733604,
      "headline": "Is Trending Stock Pfizer Inc. (PFE) a Buy Now?",
      "id": 137572330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=98819c1a576df2f09f5c64a3fc77f2947503ad5f48e1813761ff09cc7d7b4040"
    }
  },
  {
    "ts": null,
    "headline": "This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase",
    "summary": "The drugmaker may not continue to lag the market for much longer.",
    "url": "https://finnhub.io/api/news?id=e12aff363d2b4b2dd00e6c0fe00d2c02faaddfba9ecd3eced77bdd00fd29288b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763730000,
      "headline": "This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase",
      "id": 137572331,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The drugmaker may not continue to lag the market for much longer.",
      "url": "https://finnhub.io/api/news?id=e12aff363d2b4b2dd00e6c0fe00d2c02faaddfba9ecd3eced77bdd00fd29288b"
    }
  },
  {
    "ts": null,
    "headline": "PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms",
    "summary": "Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.",
    "url": "https://finnhub.io/api/news?id=057630b543edc31b29ebefc8c520e7b265def2a2f0c556ac5203d3261213b47f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763728860,
      "headline": "PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms",
      "id": 137572198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.",
      "url": "https://finnhub.io/api/news?id=057630b543edc31b29ebefc8c520e7b265def2a2f0c556ac5203d3261213b47f"
    }
  },
  {
    "ts": null,
    "headline": "The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade",
    "summary": "Earlier this week, Phillip Frost, CEO and Chairman of OPKO Health, together with Frost Gamma Investments Trust, acquired OPKO Health shares totaling US$737,747, substantially increasing his direct and indirect holdings in the company. This insider activity coincided with Jefferies downgrading OPKO Health from Buy to Hold due to concerns regarding stagnant sales guidance for Ngenla, the firm's growth hormone treatment developed with Pfizer. Let's explore how Phillip Frost's significant...",
    "url": "https://finnhub.io/api/news?id=f45e914a2222b806b5024fca4ab86c4001ff7617e62e5f1d2a0666a6a3e017ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763709246,
      "headline": "The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade",
      "id": 137572333,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Earlier this week, Phillip Frost, CEO and Chairman of OPKO Health, together with Frost Gamma Investments Trust, acquired OPKO Health shares totaling US$737,747, substantially increasing his direct and indirect holdings in the company. This insider activity coincided with Jefferies downgrading OPKO Health from Buy to Hold due to concerns regarding stagnant sales guidance for Ngenla, the firm's growth hormone treatment developed with Pfizer. Let's explore how Phillip Frost's significant...",
      "url": "https://finnhub.io/api/news?id=f45e914a2222b806b5024fca4ab86c4001ff7617e62e5f1d2a0666a6a3e017ab"
    }
  }
]